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A B S T R A C T
Introduction: Most symptomatic women with breast cancer have relatively short diagnostic intervals but
a substantial minority experience prolonged journeys to diagnosis. Atypical presentations (with
symptoms other than breast lump) may be responsible.
Methods: We examined the presenting symptoms of breast cancer in women using data from a national
audit initiative (n = 2316). Symptoms were categorised topographically. We investigated variation in the
length of the patient interval (time from symptom onset to presentation) and the primary care interval
(time from presentation to specialist referral) across symptom groups using descriptive analyses and
quantile regression.
Results: A total of 56 presenting symptoms were described: breast lump was the most frequent (83%)
followed by non-lump breast symptoms, (e.g. nipple abnormalities (7%) and breast pain (6%)); and non-
breast symptoms (e.g. back pain (1%) and weight loss (0.3%)).
Greater proportions of women with ‘non-lump only’ and ‘both lump and non-lump’ symptoms waited
90 days or longer before seeking help compared to those with ‘breast lump only’ (15% and 20% vs. 7%
respectively). Quantile regression indicated that the differences in the patient interval persisted after
adjusting for age and ethnicity, but there was little variation in primary care interval for the majority of
women.
Conclusions: About 1 in 6 women with breast cancer present with a large spectrum of symptoms other
than breast lump. Women who present with non-lump breast symptoms tend to delay seeking help.
Further emphasis of breast symptoms other than breast lump in symptom awareness campaigns is
warranted.
© 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
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Breast lump is the most common presenting symptom among
women with breast cancer and has relatively high predictive value
for malignancy [1,2]. Consequently, it has long been the focus of
public health education campaigns about cancer symptom* Corresponding author at: Epidemiology of Cancer Healthcare and Outcomes
(ECHO) Group, Research Dept. of Behavioural Science and Health, University College
London, 1-19 Torrington Place, London WC1E 7HB, UK.
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1877-7821/© 2017 The Author(s). Published by Elsevier Ltd. This is an open access artiawareness [3,4]. Although women with breast cancer typically
experience short diagnostic intervals compared to other cancer
patients, some women continue to experience long diagnostic
intervals [2,5–8]. This is concerning as longer intervals to diagnosis
have been shown to be associated with lower ﬁve-year survival of
breast cancer patients, and additionally, a prolonged diagnostic
experience may lead to poorer experience of subsequent cancer
care [9–11]. Further, inequalities in stage at diagnosis and survival
of breast cancer patients have been linked to variation in the length
of the patient interval [12–14].
Prior literature exploring reasons for delayed help-seeking
suggests that women subsequently diagnosed with breast cancercle under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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causes such as hormonal changes, trauma, or breastfeeding [15–
17]. While this provides an explanation of why some women may
experience long intervals to presentation, there has been limited
examination of diagnostic timeliness using population-based
studies and large representative samples of women with breast
cancer. Moreover, existing studies often dichotomise presenting
symptoms based on the presence or absence of breast lump,
limiting the appreciation of the large spectrum of presenting
symptoms within the ‘non-lump’ breast symptoms category [18–
21].
Motivated by the above considerations, we aimed to describe
the diverse range of presenting symptoms in a large representative
sample of women with breast cancer in England, and to examine
associations between different symptomatic presentations and the
length of diagnostic intervals. Our broader aim was to provide
underpinning evidence to inform the content and targeting of
public health campaigns and decision-support interventions in
primary care.
2. Materials and methods
2.1. Data
We analysed data from the English National Audit of Cancer
Diagnosis in Primary Care (2009–10) which collected information
on the diagnostic pathway of cancer patients in 14% of all English
general practices [22]. Patients were selected on a continuous
basis, minimising the potential for selection bias. The patient
population was representative of the age, sex, and cancer case-mix
of incident cancer patients in England, and participating practices
were also comparable to non-participating practices in respective
(former) Cancer Networks [22,23]. Our analysis sample comprised
2316 women with breast cancer with complete and valid
information on age, ethnicity, and presenting symptoms. Among
these women, 1883 (81%), 2201 (95%), and 2002 (86%) had
complete information on the patient interval, the primary care
interval, and the number of pre-referral consultations respectively
(Supplementary Fig. A.1). Women with missing interval or pre-
referral consultation data were less likely to have presented in
general practice, or were older (70 years or over) without evidence
for variation by ethnicity, symptom group, or number of symptoms
(data not shown).
2.2. Presenting symptoms
As part of the audit, general practitioners within participating
practices provided free-text information on the main presenting
symptom(s) of patients, based on information in their records.
Informed by the principles of natural language processing (NLP),
free-text descriptions were coded into symptoms without using
any prior construct deﬁnitions or restrictions [24]. Symptom were
initially assigned by MMK, and subsequently veriﬁed by GL and
GPR. Where there was diverging opinion, consensus was reached
by discussion.
2.3. Diagnostic intervals
As previously reported, the length of the patient and primary
care intervals were derived based on information in the patients’
primary care records [25,26]. Concordant with international
consensus statements, the patient interval was deﬁned as the
number of days between symptom onset and the ﬁrst presenta-
tion, and the primary care interval as the number of days between
ﬁrst presentation and the ﬁrst specialist referral [27]. The number
of pre-referral consultations was also examined, as a stronglycorrelated marker of the length of the primary care interval [6].
Pre-referral consultations were parameterised as a binary outcome
(1 pre-referral consultation vs 2 or more pre-referral consulta-
tions) as the great majority of women (90%) had a single
consultation.
2.4. Analytic methods
Firstly, we described the frequency of recorded presenting
symptoms and associated exact conﬁdence intervals, and the
distribution of the patient and primary care intervals for each
symptom among women with complete interval values. Beyond
summarising mean, median and key centile interval values, we
have also reported the proportion of women with each symptom
that experienced 2 or more pre-referral consultations [6].
Additionally, we calculated the proportion of women with interval
values exceeding 90 days, given prior evidence of poorer survival
among women experiencing diagnostic intervals of 3 months or
longer [11].
We developed a taxonomy of presenting symptoms by
classifying individual symptoms into three main symptom
categories: (a) breast lump, (b) non-lump breast symptoms (includ-
ing breast pain, breast skin or shape abnormalities and nipple
abnormalities), and (c) non-breast symptoms (including fatigue,
breathlessness, axillary symptoms, neck lump, and back pain) (see
Fig. 2 and Fig. A.2 in Supplementary materials). Some women had
multiple symptoms across different symptom categories. From the
resulting seven combinations of the three symptom categories, we
focused on the four largest groups (‘lump’, ‘lump and non-lump’,
‘non-lump’, and ‘non-breast’).
We used Kruskal-Wallis and Chi-squared tests to compare
observed diagnostic intervals and the number of pre-referral
consultations by symptom groups, and other covariates. Subse-
quently, regression was used to examine the variation in patient
and primary care intervals by symptom group adjusted for age and
ethnicity. Speciﬁcally, as the outcome data (length of patient
interval and primary care interval) were highly right-skewed, a
continuity correction and log-transformation was applied to both
variables before using quantile regression across different centiles
of interest, and signiﬁcance testing was based on bootstrapping.
Detailed methods and ﬁndings of quantile regression modelling
are available in the Supplementary materials. All analyses were
conducted in STATA SE v.13 (StataCorp, College Station, TX, USA).
3. Results
3.1. Symptom signature of breast cancer – individual symptoms
A total of 2316/2783 (83%) of symptomatic women with breast
cancer were included in the analysis (see Supplementary Fig. A.1
for sample derivation). Among them, 2543 symptoms were
recorded, averaging 1.1 symptoms per woman. A total of 56
distinct presenting symptoms were reported in the study
population (Table 1), in 95 unique phenotypes. Breast lump was
the most common symptom, recorded in about four-ﬁfths of all
women (83%). The next most commonly reported presenting
symptoms were nipple abnormalities (7%), breast pain (6%), and
breast skin abnormalities (2%).
Overall, 164 women (9% of those with patient interval values)
waited longer than 90 days before seeking help. Among the larger
non-lump breast symptoms, more than one in ﬁve women with
breast ulceration (50%), nipple abnormalities (23%) and breast
infection or inﬂammation (21%) had patient intervals of more than
90 days (Table 1). In contrast to the substantial proportion of
women with patient intervals longer than 3 months (9%, as above),
only 2% of women had recorded primary care interval values of
Table 1
Frequencies of the 23 most common symptoms (with a relative frequency of 0.2% or more) among 2316 women with breast cancer included in analysis; see Table A.1 in the
Supplementary material for full list of 56 symptoms.
Symptom Symptom signature and
frequency
Pre-presentation Post-presentation
No of
women
% Relative
frequency (95% CI)
Patient
Interval
Median (IQR)
90thb
(n = 1883)
% Patient Interval
>90 daysb
(95% CI)
Primary Care
Interval
Median (IQR)
90thb
(n = 2201)
% Primary Care
Interval >90 daysb
(95% CI)
% 2+ pre-referral
consultationsb (n = 2002)
Breast lump 1922 83.0% (81.4–84.5%) 7 (1–27) 75 8% (7–9%) 0 (0–0) 3 1% (1–2%) 6%
Nipple abnormalities 158 6.8% (5.9–7.9%) 17 (2–71)
275
23% (17–31%) 0 (0–1) 7 1% (0.4–5%) 12%
Breast pain 149 6.4% (5.5–7.5%) 10 (3–41) 96 12% (8–19%) 0 (0–3) 34 3% (1–7%) 20%
Breast skin abnormalities 46 2.0% (1.5–2.6%) 13 (1–30)
129
10% (4–24%) 0 (0–1) 3 2% (0.4–12%) 8%
Axillary lump 27 1.2% (0.8–1.7%) 2.5 (0–12) 15 0% (0–15%) 0 (0–14) 34 4% (1–18%) 36%
Breast ulceration 25 1.1% (0.7–1.6%) 122 (0–276)
594
56% (27–81%) 0 (0–1) 1 0% (0–15%) 7%
Back pain 24 1.0% (0.7–1.5%) 9.5 (1–51)
107.5
10% (3–30%) 21 (0–105)
145
26% (13–46%) 65%
Breast contour
abnormalities
17 0.7% (0.5–1.2%) 5 (4–18) 184 15% (4–42%) 0 (0–1) 3 0% (0–20%) 7%
Breast infection or
inﬂammation
15 0.6% (0.4–1.1%) 2.5 (0–30)
366
21% (8–48%) 9 (0–23) 37 7% (1–31%) 60%
Breast swelling 14 0.6% (0.4–1.0%) 3.5 (0–14)a 10% (2–40%) 0 (0–3.5) 8 0% (0–24%) 15%
Musculoskeletal pain 14 0.6% (0.4–1.0%) 0.5 (0–22)a 10% (2–40%) 54 (0–187.5)
399
25% (9–53%) 75%
Breathlessness 11 0.5% (0.3–0.8%) 5 (0–35.5)a 0% (0–49%) 1 (0–10.5)a 0% (0–32%) 57%
Breast rash 10 0.4% (0.2–0.8%) 0 (0–16)a 0% (0–39%) 0 (0–7)a 0% (0–32%) 20%
Neck lump or lymph node
abnormalities
9 0.4% (0.2–0.7%) 0 (0–10)a 0% (0–39%) 4.5 (0–19.5)a 0% (0–32%) 29%
Abdominal pain 8 0.3% (0.2–0.7%) 39 (18–62)a 17% (3–56%) 3 (2–6)a 0% (0–43%) 71%
Other breast abnormalities 8 0.3% (0.2–0.7%) 6 (0–8)a 0% (0–43%) 0 (0–98)a 33% (10–70%) 14%
Chest pain 8 0.3% (0.2–0.7%) 18 (10–43)a 0% (0–32%) 24 (9.5–83)a 25% (7–59%) 75%
Fatigue or weakness 7 0.3% (0.1–0.6%) 10.5 (1.5–
33)a
0% (0–49%) 2 (0–27)a 14% (3–51%) 29%
Weight Loss 6 0.3% (0.1–0.6%) 56 (51–61)a 0% (0–66%) 18 (11–22)a 0% (0–43%) 60%
Cough 6 0.3% (0.1–0.6%) 5.5 (0–11)a 0% (0–66%) 13.5 (6.5–38)a 0% (0–49%) 60%
Axillary pain 5 0.2% (0.1–0.5%) 15 (0–126)a 33% (6–79%) 5 (1–8)a 0% (0–43%) 40%
Breast bruising 5 0.2% (0.1–0.5%) 7 (7–14)a 0% (0–43%) 0 (0–8)a 0% (0–43%) 40%
Oedema of upper limb 5 0.2% (0.1–0.5%) 76 (19–133)a 50% (10–91%) 0.5 (0–1)a 0% (0–49%) 0%
Total 2316 – 7 (1–28) 80 9% (8–10%) 0 (0–1) 7 2% (1–2%) 10%
NB Symptom frequencies do not add up to 100% as some women had more than one symptom.
a 90th centile PI and PCI values not shown for symptoms where there were <10 patients with non-missing values.
b 19%, 5%, and 14% of all observations had missing information on the patient interval, the primary care interval, and the number of pre-referral consultations respectively.
For exact proportion by symptom please see Table A.1 in the Supplementary material.
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symptoms such as non-speciﬁc breast abnormalities, back pain,
musculoskeletal pain, chest pain, and fatigue or weakness.
3.2. Variation in diagnostic intervals by major symptom group
The vast majority (99%) of women belonged to one of four
symptom groups: ‘lump only’ (76%); ‘non-lump only’ (11%); ‘both
lump and non-lump’ (6%); and ‘non-breast symptoms’ (5%) (Fig. 1).
There was no difference in frequency of symptom groups by age
group of ethnicity (Supplementary Table A.2).
As most of the variation in interval length between different
symptom groups was concentrated at the long right tail of the
distribution, we hereafter describe the 90th centile values in
addition to the median value. Overall, the patient interval was
substantially longer than the primary care interval (median 7 vs 0
days, and 90th centile 80 vs 7 days, respectively; Table 2 and Fig. 2).
3.2.1. Patient interval
There was strong evidence for variation in the patient interval
by symptom group (p < 0.001). Women with ‘lump only’ symp-
toms had median (90th centile) patient interval values of 7 (66)
days. In contrast, those with ‘non-lump only’ or ‘both lump and
non-lump’ symptoms had median (90th centile) intervals of 12
(126) days and 14 (276) days, respectively, while women with ‘non-breast symptoms’ had shorter intervals (of 4 (59) days) (Table 2).
Observed patterns of variation in the patient interval by symptom
group remained largely unchanged after adjusting for age group
and ethnicity. There was no evidence for variation in the length of
the patient interval by age or ethnicity at any of the quantile points
examined (Supplementary Table A.4).
3.2.2. Primary care interval
Observed primary care interval values also varied by symptom
group: women presenting with ‘lump only’ had the shortest
median (90th centile) intervals (0 (2) days), while those with ‘non-
breast’ symptoms had the longest intervals (7 (105) days),
respectively (Table 2). Concordant patterns of variation by
symptom group were apparent when examining the proportion
of women with 2 or more pre-referral consultations (Supplemen-
tary Table A.3). Adjusting for differences in age group and ethnicity,
symptom groups other than the ‘lump only’ group had longer
intervals to referral, but these differences were only signiﬁcant in
the upper centiles (Supplementary Table A.4 and Fig. 2).
4. Discussion
About 1 in 6 women with breast cancer presented without a
breast lump, instead experiencing a wide spectrum of symptoms
before seeking help. The length of the patient and the primary care
Table 2
Descriptive statistics of the patient interval (n = 1878a and primary care interval
(n = 2194a) in symptomatic women with breast cancer. Quantile regression
modelling output is presented in the Supplementary material.
Symptom group Median (IQR) 90th P-value % women >90 days
(95% CI)
Patient Intervala
All women 7 (1–28) 80 – 9% (8–10%)
Breast lump only 7 (1–24) 66 <0.001b 7% (6–9%)
Non-lump only 12 (2–46) 126 15% (11–20%)
Lump and non-lump 14 (3–54) 276 20% (14–29%)
Non-breast symptoms 4 (0–18) 59 6% (2–12%)
White 7 (1–28) 80 0.509c 9% (8–10%)
Non-white 6 (0–30) 78 8% (5–14%)
<50 years 7 (1–27) 66 0.148c 7% (5–10%)
50–69 years 7 (1–25) 72 8% (6–10%)
70+ years 7 (1–31) 92 11% (9–13%)
Primary Care Intervala
All women 0 (0–1) 7 – 2% (1–2%)
Breast lump only 0 (0–0) 2 <0.001b 1% (1–2%)
Non-lump only 0 (0–1) 21 1% (0.4–4%)
Lump and non-lump 0 (0–1) 18 4% (2–8%)
Non-breast symptoms 7 (0–34) 105 10% (6–17%)
White 0 (0–1) 7 0.620c 2% (1–2%)
Non-white 0 (0–0) 10 1% (0.3–5%)
<50 years 0 (0–1) 15 0.016c 3% (2–5%)
50–69 years 0 (0–0) 4 1% (1–2%)
70+ years 0 (0–1) 3 1% (1–2%)
Bold denotes p < 0.05.
a K19% and 5% of women had missing information on the patient interval and the
primary care interval respectively.
b Kruskal-Wallis tests.
c Chi-squared tests.
Fig. 1. Venn diagram depicting the four largest symptom groups in 2316 breast cancer patients. The three shaded groups in red were not investigated due to small numbers:
breast lump and non-breast symptoms (n = 12), non-lump breast symptoms and non-breast symptoms (n = 7), and breast lump, non-lump breast symptoms, and non-breast
symptoms (n = 1). The full symptom taxonomy is presented in Fig. A.2. in the Supplementary material (For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)
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centiles of the distribution. Women in the ‘non-lump only’ and
‘both lump and non-lump’ symptom groups had longer median
patient intervals compared to those with ‘breast lump only’.
Similar associations were seen post-presentation, although on
average women had appreciably shorter primary care intervals
than patient intervals.
To our knowledge, this is the ﬁrst and largest study to examine
associations between a range of presenting symptoms of breast
cancer and the length of the patient and the primary care intervals.
The present analysis substantially ampliﬁes previous ﬁndings in
this ﬁeld, providing evidence of notable differences in diagnostic
timeliness by the symptoms of breast cancer [9,16]. Regarding the
symptom signature of breast cancer, a previous study using Read-
coded electronic primary care data reported similar proportions of
non-lump breast symptoms to those observed in our study [2], but
we have been able to describe a wide range of presenting
symptoms in substantially greater detail than the categorisations
used to date.
The study setting is within a publicly funded health system
where patients have free access to primary care services and
primary care physicians act as gate-keepers to specialist services.
We would not expect health system factors to affect the process of
symptom appraisal by women, but patient intervals may be longer
in healthcare systems without universal healthcare coverage. In
contrast, although in theory gate-keeping may be associated with
prolonged primary care intervals, in practice we observed very
short primary care intervals for the majority of women in our study
[28]. Therefore we do not believe that the context of our study
substantially affects the relevance of the ﬁndings, particularly in
Fig. 2. Quantile plot distribution of the patient (left) and primary care (right) intervals by symptom group. Note that curves tend to separate towards the upper end of the
distribution. Data relate to the four largest presenting symptom groups (see main text). (Please refer to the web version of this article for a colour version.)
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delay.
There are several limitations that should be acknowledged. The
validity and completeness of symptom information is dependent
on patients accurately recalling and describing their symptoms
during the consultation, and on doctors accurately interpreting
and recording them. Additionally, as patient records were
examined retrospectively (and in the knowledge of the patient’s
diagnosis), non-speciﬁc, particularly non-breast, symptoms may
have been under-captured by the audit. There were missing
outcome data regarding intervals and number of consultations for
a minority of women, in proportions comparable to previous
studies in this ﬁeld [7,29–31]. Women who did not ﬁrst present in
primary care and were older were more likely to have missing data
but were otherwise similar across other characteristics of interest.
We were unable to examine variation in diagnostic intervals by
level of deprivation or other patient-level characteristics such as
health literacy or history of screening participation as this
information was not captured by the audit, although the length
of patient intervals by symptom may vary by socio-economic
status [12,32]. Although we were able to describe the overall
symptom signature of breast cancer in appreciable detail,
associations with diagnostic timeliness measures were analysed
using aggregate symptom groups due to sample size limitations
regarding rarer individual symptoms, particularly non-breast
symptoms. Lastly, while data relate to a recent annual period,
further monitoring of associations between symptoms and
diagnostic intervals in more recent cohorts will be useful.
The present study provides detailed evidence about the
symptom signature of breast cancer, and the frequencies and
diagnostic intervals associated with different symptoms, which
could inform the design of public health campaigns. Existing
examples of population- or person-level breast awareness
interventions that encompass both lump and non-lump symptoms
of the breast include the English breast “Be Clear on Cancer”
campaign and the “Promoting Early Presentation” intervention
[33–35]. Our ﬁndings support a continued shift in emphasis of
awareness interventions to encompass the likely importance of
‘non-lump’ breast symptoms.
Beyond considering the symptom signature and associated
diagnostic intervals, the design of awareness campaigns should
also reﬂect the predictive value of symptoms for a givenmalignancy. Currently, there is little relevant evidence beyond
that for breast lump, but some non-lump breast symptoms (such as
nipple eczema or breast ulceration) may have equal or greater
positive predictive values for breast cancer [36,37].
Women in the ‘both lump and non-lump’ group had longer
patient intervals compared to those with ‘breast lump only’ group.
This is somewhat puzzling given that breast lump, which is
associated with shorter intervals, is present in both groups. This
may reﬂect a higher tendency for women normalise a lump in the
breast in the presence of other non-lump breast symptoms [12].
Relatedly, previous research indicates that among women with
prolonged patient intervals (12 weeks or longer), some had initially
experienced non-lump breast symptoms and then had subse-
quently developed a lump by the time of (delayed) presentation
[18]. Prospective designs such as those employed by the SYMPTOM
studies in England may help explore the time sequence of
symptom occurrence and diagnostic intervals, although logistical
constraints may limit sample size and power [30].
The majority of women had much shorter intervals post-
presentation than pre-presentation (1 in 2 women with breast
cancer in our study had a primary care interval of 0 days) and there
was no evidence for variation in the median primary care interval
by symptom group. The small minority of women who presented
with ‘non-breast symptoms’ (e.g. back pain or breathlessness)
however had substantially longer primary care intervals compared
to those with breast lump or non-lump breast symptoms.
Shortening diagnostic intervals in such women will improve
patient experience, but may not lead to better clinical outcomes
given that distant symptoms might represent late stage disease
[10]. Identifying these women is also likely to be challenging, due
to the low predictive values of these symptoms for breast cancer.
New diagnostic services for non-speciﬁc symptoms such as the Z
Danish three-legged strategy’ and those being piloted by the those
being piloted by Accelerate, Coordinate, Evaluate (ACE) initiative in
England may be of particular value in this regard [38,39].
5. Conclusions
In conclusion, this study provides a detailed description of the
symptom signature at presentation among women subsequently
diagnosed with breast cancer, and conﬁrms an association
between non-lump presenting symptoms of the breast and
M.M. Koo et al. / Cancer Epidemiology 48 (2017) 140–146 145prolonged diagnostic intervals. Our ﬁndings highlight the need for
healthcare interventions to support the diagnostic process in
women with atypical presentations; and support efforts to focus
on non-lump breast symptoms through public health education
campaigns in order to facilitate earlier presentation.
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